LI-TASTE Study: Light for Taste
Conditions: Multiple Myeloma Interventions: Device: LX2.3 Laser and LED Photobiomodulation System; Device: LX2.3 Laser and LED Photobiomodulation System Sham-PBMT Setting Sponsors: Academic Centre for Dentistry in Amsterdam Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 14, 2024 Category: Research Source Type: clinical trials
Biomechanical and Metabolic Assessment Pre and Post Vertebroplasty in Multiple Myeloma Patients With Vertebral Collapse
Conditions: Multiple Myeloma Sponsors: Centro di Riferimento Oncologico - Aviano Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 13, 2024 Category: Research Source Type: clinical trials
Clinical Study of Reduced-dose Pomalidomide and Cyclophosphamide Combined With Dexamethasone in the Treatment of Patients With Debilitating RRMM
Conditions: Multiple Myeloma in Relapse Interventions: Drug: Pomalidomide, cyclophosphamide combined with dexametha Sponsors: Shanxi Bethune Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 13, 2024 Category: Research Source Type: clinical trials
Dara-PD in the Treatment of Patients With First Relapse of Multiple Myeloma
Conditions: Multiple Myeloma; First Relapse Sponsors: FengYan Jin; Affiliated Hospital of Hebei University; Second Hospital of Shanxi Medical University; Shandong Cancer Hospital and Institute; First Affiliated Hospital of Jinan University; Sun Yat-sen University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2024 Category: Research Source Type: clinical trials
European Rare Blood Disorders Platform (ENROL)
Conditions: Anemia; Bone Marrow Failure; Bleeding Disorder; Iron Metabolism Disorders; Myeloma; Lymphoid Neoplasm; Myeloma, Malignant; Leukemia; Anemia, Sickle Cell; Thalassemia; Blood Cancer; Red Cell Membrane and Enzyme Abnormalities Interventions: Other: Collection of clinical and laboratory data from EHR. Sponsors: Hospital Universitari Vall d ' Hebron Research Institute; ERN-EuroBloodNet (European Reference Network on Rare Hematological Diseases Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 9, 2024 Category: Research Source Type: clinical trials
Plan Development for Giving Teclistamab in the Outpatient Setting
Conditions: Multiple Myeloma; Relapsed Cancer; Refractory Cancer Interventions: Drug: Teclistamab; Drug: Tocilizumab Sponsors: University Health Network, Toronto; Janssen Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 9, 2024 Category: Research Source Type: clinical trials
ICOPE Program Feasibility in the Management of Myeloma Patients
Conditions: Frailty; Multiple Myeloma Interventions: Other: ICOPE Monitoring Sponsors: University Hospital, Toulouse Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials
Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma
Conditions: Myeloma Multiple Interventions: Drug: Bortezomib-bendamustine-melphalan Sponsors: Uppsala University; Uppsala County Council, Sweden; Dalarna County Council, Sweden Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials
Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma
Conditions: Multiple Myeloma Interventions: Drug: Lipo-MIT combination regimen Sponsors: Affiliated Hospital of Nantong University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 7, 2024 Category: Research Source Type: clinical trials
Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma
Conditions: Determining Safety and Maximum Tolerated Dose (MTD) of Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma Interventions: Biological: Anti-BCMA CAR-NK Sponsors: Shahid Beheshti University of Medical Sciences Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 5, 2024 Category: Research Source Type: clinical trials
EMN Sample Project
Conditions: Multiple Myeloma; Smoldering Multiple Myeloma; Plasma Cell Leukemia; Extramedullary Myeloma; MGUS Interventions: Other: storage of biological samples Sponsors: Stichting European Myeloma Network; Janssen, LP Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 1, 2024 Category: Research Source Type: clinical trials
The Unmet Needs of Cancer Survivors in Ausl IRCCS Reggio Emilia
Conditions: Cancer; Breast Cancer; Prostate Cancer; Thyroid Cancer; Colorectal Cancer; Lymphoma; Multiple Myeloma; Neoplasms Interventions: Other: Focus Groups or Interviews Sponsors: University of Modena and Reggio Emilia; Azienda USL - IRCCS di Reggio Emilia Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 1, 2024 Category: Research Source Type: clinical trials
European Myeloma Network (EMN) Sample Project
Conditions: Multiple Myeloma; Smoldering Multiple Myeloma; Plasma Cell Leukemia; Extramedullary Myeloma; MGUS Interventions: Other: storage of biological samples Sponsors: Stichting European Myeloma Network; Janssen, LP Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 1, 2024 Category: Research Source Type: clinical trials
A Study to Evaluate Efficacy and Safety of Alnuctamab Compared to Standard of Care Regimens in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)
Conditions: Multiple Myeloma Interventions: Drug: Alnuctamab; Drug: Pomalidomide; Drug: Daratumumab; Drug: Elotuzumab; Drug: Carfilzomib; Drug: Dexamethasone Sponsors: Celgene Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 31, 2024 Category: Research Source Type: clinical trials
A Phase I/II Study of GC012F in Patients With Relapsed/Refractory Multiple Myeloma
Conditions: Multiple Myeloma Interventions: Biological: GC012F Sponsors: Gracell Biotechnologies Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 31, 2024 Category: Research Source Type: clinical trials
